Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2021-04-05 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2021-04-05 English
Immediate Report of Meeting to be held on April 5, 2021,proxy statement
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a "PROXY" solicited on behalf of the Board of Directors for an "Extraordinary General Meeting of Shareholders to be held on April 5, 2021." It contains voting instructions for various proposals, including amendments to the Compensation Policy and an equity grant. This content is characteristic of materials used to solicit shareholder votes prior to a general meeting. The closest matching category is Proxy Solicitation & Information Statement (PSI). While it relates to an AGM, the specific nature of soliciting votes via a proxy form points directly to PSI, which covers materials sent to shareholders to request votes.
2021-02-27 English
Immediate Report of Meeting to be held on April 5, 2021,proxy statement
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled 'FORM 6-K' and is a 'REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934'. The content announces an 'Extraordinary General Meeting of Shareholders' and includes the 'Notice of Extraordinary General Meeting and Proxy Statement'. A Proxy Statement (materials sent to shareholders to request votes) is directly related to shareholder meetings and voting procedures. While the Form 6-K is a general regulatory filing, the primary, specific purpose of the attached materials is soliciting votes for an EGM, which aligns best with the Proxy Solicitation & Information Statement category (PSI). Since the document is substantial (46k chars) and contains the full proxy statement details, it is the actual solicitation material, not just an announcement of its release (RPA/RNS).
2021-02-27 English
Immediate Report of Meeting to be held on April 5, 2021,proxy statement
AGM Information Classification · 98% confidence The document explicitly states it is giving notice of the 'convening of meeting' for an 'extraordinary meeting' scheduled for 05/04/2021. It details the agenda items, which involve approving amendments to the Compensation Policy and an equity compensation grant, and mentions attached documents like a Proxy Statement ('Proxy_isa.pdf'). This content is directly related to soliciting shareholder votes and providing necessary information ahead of a general meeting. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. While it relates to AGM topics (compensation), the primary function here is the notice and solicitation for the extraordinary meeting.
2021-02-27 English
6-K
Regulatory Filings
2021-02-26 English
Regulatory Filings 2021
Regulatory Filings
2021-02-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.